[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cholestatic-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cholestatic-liver-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,75,103,126,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644494","phase-4-vitamin-d2-versus-vitamin-d2-plus-calcitriol-in-cholestatic-children-with-vitamin-d-deficiency-100644494",false,"NCT07670611","VITAMIN D2 VERSUS VITAMIN D2 PLUS CALCITRIOL IN CHOLESTATIC CHILDREN WITH VITAMIN D DEFICIENCY","ACCELERATED CORRECTION OF VITAMIN D DEFICIENCY IN CHOLESTATIC CHILDREN: A COMPARATIVE TRIAL OF VITAMIN D2 MONOTHERAPY VERSUS COMBINATION THERAPY WITH CALCITRIOL","VITD-CHOL","Inclusion Criteria:\n\n* Patients younger than 18 years of age.\n* Patients diagnosed with cholestasis, defined as direct\u002Fconjugated bilirubin \\>1 mg\u002FdL for more than 1 month.\n* Patients diagnosed with chronic liver disease.\n* Patients with vitamin D deficiency, defined as serum 25-hydroxyvitamin D (25-OHD) level \\\u003C20 ng\u002FmL, according to the Endocrine Society Clinical Practice Guideline.\n\nExclusion Criteria:\n\n* Pre-existing hypercalciuria, screened by urine calcium testing before enrollment.\n* Patients with benign or malignant tumors.\n* Patients with renal tubular defects, screened by electrolyte testing before enrollment.\n* Patients currently receiving anticonvulsant therapy.\n* Patients who do not attend scheduled follow-up visits.","ALL","18 Years",{"count":20,"type":21},54,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn whether adding calcitriol to vitamin D2 can improve vitamin D deficiency in children with cholestasis and chronic liver disease. Cholestasis is a condition in which bile flow is reduced, which can make it difficult for the body to absorb and process vitamin D. The study will also learn about the safety of using vitamin D2 together with calcitriol.\n\nThe main questions it aims to answer are:\n\n* Does vitamin D2 plus calcitriol increase blood 25-hydroxyvitamin D (25-OHD) levels more than vitamin D2 alone after 3 months of treatment?\n* Does vitamin D2 plus calcitriol help more children reach an adequate vitamin D level by 3 and 6 months?\n* What medical problems, especially high calcium or high phosphorus levels, occur during treatment?\n\nResearchers will compare children who receive vitamin D2 alone with children who receive vitamin D2 plus calcitriol to see which treatment improves vitamin D levels more effectively and safely.\n\nParticipants will:\n\n* Take vitamin D2 alone or vitamin D2 plus calcitriol as assigned by randomization\n* Visit the clinic for study assessments at the start of the study, at 3 months, and at 6 months\n* Have blood tests to measure vitamin D levels, calcium, phosphorus, parathyroid hormone, liver function, and other safety markers\n* Have their treatment reviewed at 3 months; participants whose vitamin D level remains low may have their treatment adjusted according to the study plan\n* Bring back medication packages so researchers can check how regularly the study medicines were taken",[27,28,29,30],"Cholestatic Liver Disease","Chronic Liver Disease (CLD)","Vitamin D Deficiency","Children",[32,33,34,35,36],"cholestasis","pediatrics","vitamin d deficiency","Calcitriol","25-Hydroxyvitamin D2","RECRUITING","2026-06-22",{"date":40,"type":41},"2026-06-26","ACTUAL",{"date":43,"type":41},"2026-04-28",{"date":45,"type":21},"2027-04-20",{"name":47,"class":48},"Chulalongkorn University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100617328","defining-the-genetic-drivers-of-adult-onset-cholestatic-liver-disease-100617328","NCT07317193","DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE","FIRST","Inclusion Criteria:\n\nCases:\n\n* Adults, aged \\> 18 years with:\n\n  1. persistent or intermittent elevations in serum alkaline phosphatase (ALP) or gamma-glutamyltransferase (GGT) for at least six months not explained following standard diagnostic assessment adhering to the guidelines of the European Association for the Study of the Liver (EASL), or with a positive family history of unexplained cholestasis or hepato-biliary cancer, negative to previous genetic tests (targeted panel for PFIC genes or WES);\n  2. primary sclerosing cholangitis (PSC) with unusual features: small-duct PSC, non-typical radiological findings according to radiological guidelines on PSC, absence of concomitant inflammatory bowel disease, negative to previous genetic tests (targeted panel for PFIC genes or WES) or who didn't perform previous genetic test;\n  3. primary biliary cholangitis (PBC) without specific anti-mitochondrial antibodies, negative to previous genetic tests (targeted panel for PFIC genes or WES) or who didn't perform previous genetic test.\n* Signature of informed consent\n\nControls:\n\n-Blood donors (age 18-65 years) without clinical signs of liver diseases based on the collected clinical parameters: anthropometric (BMI\\>18 and \\\u003C25), haematological (Hb, white blood cells, platelets within the reference range), biochemical traits (albumin, bilirubin, AST, ALT, GGT, ALP within the reference range), medical history (negative for chronic or concomitant diseases, including immunological diseases)\n\nExclusion Criteria:\n\nCases:\n\n* Patients who do not possess the above inclusion criteria or have at least one of the following exclusion criteria:\n* an already known genetic diagnosis explaining the clinical phenotype\n* affected by other causes of liver disease such as viral or autoimmune hepatitis\n\nControls:\n\n-Blood donors with clinical signs of liver diseases",true,"65 Years",{"count":60,"type":21},60,[62],"NA","Cholestatic disease in adults comprises a heterogeneous group of conditions characterized by intra- or extrahepatic alterations of bile flow that can lead to fibrosis or hepatic decompensation. Due to the heterogeneity of clinical manifestation, which is sometimes very subtle, diagnosis based on clinical, histological, and radiological evaluation is often very complicated. Genetic testing can be helpful in identifying the cause of the clinical phenotype, thereby allowing for targeted follow-up adequate to the patient's specific characteristics and risk factors. Although the utility of genetic analysis has been well documented for other liver diseases or in pediatric cohorts of children with cholestatic disease, the use and benefits of genetic testing in adults with cholestatic disease are still little explored and investigated. In this context, through the use of whole-genome sequencing (WGS), the FIRST project aims to evaluate the role of rare genetic variants in the pathogenesis of cholestatic disease and the utility of WGS in defining a genetic diagnosis.",[27,65],"Progressive Familial Intrahepatic Cholestasis","2026-03-23",{"date":68,"type":41},"2026-03-27",{"date":70,"type":41},"2025-11-01",{"date":72,"type":21},"2026-10-31",{"name":74,"class":48},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":49},"100442753","phase-1-hepatic-impairment-with-cirrhosis-due-to-cholestatic-liver-disease-100442753","NCT05045482","Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease","A Phase 1, Open-Label Extension Groups Study in Subjects Having Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease","Inclusion Criteria:\n\nFor all subjects:\n\n1. Ability to comprehend and willingness to sign a written ICF for the study.\n2. Male or female aged 18 to 80 years (inclusive) at the time of signing the ICF.\n3. Body mass index within the range 18.0 to 48.0 kg\u002Fm2 (inclusive) at screening.\n4. Females must be non-pregnant, non-lactating and of non-childbearing potential or using highly efficient contraception for the full duration of the study.\n5. Females of child-bearing potential and males must agree to use contraception for the full duration of the study.\n6. Ability to swallow and retain oral medication.\n\n   For Subjects in Groups 8 and 9 (Hepatic impairment group but with cirrhosis from cholestatic liver disease):\n7. Participants having documented history of hepatic impairment with cirrhosis due to cholestatic liver disease in Groups 8 and 9 will be classified in sub groups at screening based on CPT score. If the hepatic impairment classification for the subject is not the same at screening and Day -1, enrolment of the subject into a hepatic category group will be at the discretion of the hepatology Investigator.\n8. Laboratory test values for hepatic impairment subjects Groups 8 (8A, 8B, 8C) and 9 (9A, 9B, 9C) must be clinically acceptable to the Investigator and meet all the following parameters at Screening:\n\n   1. ALT\u002FAST value ≤ 10 × upper limit of normal (ULN)\n   2. Absolute neutrophil count (ANC) ≥ 750\u002Fmm3\n   3. Platelets ≥ 25,000\u002Fmm3\n   4. Hemoglobin ≥ 8 g\u002FdL\n   5. α-fetoprotein \\\u003C 50 ng\u002FmL or 50-80 ng\u002FmL with negative imaging study (US, CT, MRI).\n\n   For Subjects in Groups 8D and 9D (normal hepatic function groups):\n9. Subjects should be in good health as determined by no clinically significant findings in the medical history, physical examination, vital signs, 12-lead electrocardiograms (ECGs), or laboratory examinations at Screening or Check-in.\n10. Laboratory test values within normal limits or considered not clinically significant by the Investigator for subjects with normal hepatic function including ALT\u002FAST \\\u003C 1.2 × ULN at screening.\n\nExclusion Criteria:\n\nFor all subjects:\n\n1. Any significant, unstable medical condition or other instability that would prevent the subject from participating in the study as determined by the Investigator or designee.\n2. History of malignancy of any type in the last 3 years of screening, with the exception of the following: in situ cervical or breast cancer or surgically excised non-melanoma skin cancers (i.e. basal cell or squamous cell carcinoma).\n3. History of stomach or intestinal surgery or resection within the six months prior to screening that would potentially alter absorption and\u002For excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed).\n4. History of any significant drug allergy (such as anaphylaxis) deemed clinically relevant by the Investigator.\n5. Any major surgery within 3 months of screening.\n6. Donation of blood or blood products within 3 months prior to screening.\n7. Current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment or symptoms of active infectious disease within the two weeks prior to screening.\n8. Use or intend to use any medications\u002Fproducts known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, within 21 days prior to screening, unless deemed acceptable by the Investigator.\n9. Receiving or has received any investigational drug within the 30 days or 5 half-lives (whichever is longer), before receiving Saroglitazar Magnesium.\n10. Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73m2 by modification of diet in renal disease (MDRD) formula at screening.\n11. Positive alcohol breath test at the time of check-in or those subjects who have current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance or subject safety.\n12. Positive test for drugs of abuse at screening or admission. Subjects with a positive test based on a prescribed medication may be enrolled.\n13. Any subject with poor peripheral venous access\n14. Receipt of blood products within 1 month prior to check in.\n15. Human immunodeficiency virus (HIV) type 1 antibody positive at screening for all groups.\n\n    For Subjects in Groups 8 and 9 (Hepatic impairment group but with cirrhosis from cholestatic liver disease):\n16. Other known cause of liver disease such as NASH, alcoholic steatohepatitis (ASH), autoimmune hepatitis, or acute or chronic viral hepatitis as determined by the Investigator and subject's medical records.\n17. Subjects who have had a change in hepatic disease status within 30 days of screening, as documented by the participant's medical history and deemed clinically significant by the Investigator.\n18. Subjects having -\n\n    1. History of gastrointestinal bleeding within 1 month prior to screening.\n    2. Current functioning organ transplant.\n    3. Evidence of severe ascites requiring frequent paracentesis in the opinion of investigator.\n19. Subjects who use or intend to use any over the counter (vitamins, minerals, and phytotherapeutic\u002Fherbal\u002Fplant-derived preparations) or prescription medications within 30 days or 5 half-lives (whichever is longer) prior to enrolment, with the exception of hormone replacement therapy and therapies for hepatic disease and treatments of associated disorders that have been stable for at least 30 days prior to screening and until Day 1, unless deemed acceptable by the Investigator (or designee).\n\n    For Subjects in Group 8A (Mild hepatic impairment group) and 8B (Moderate impairment group)\n20. Total bilirubin \\> 5×ULN\n\n    For Control with Normal Hepatic Function:\n21. Subjects who have taken any prescription medications or over-the-counter medications, including herbal products, within 14 days prior to start of study drug dosing, with the exception of vitamins, acetaminophen, hormonal contraceptive medications and\u002For any other over-the-counter product approved by the Investigator.","80 Years",{"count":84,"type":21},30,[86],"PHASE1","A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease",[89,90,27],"Hepatic Impairment","Cirrhosis",[89,92,90,27],"Saroglitazar Magnesium","2026-02-13",{"date":95,"type":41},"2026-02-17",{"date":97,"type":41},"2021-10-21",{"date":99,"type":21},"2026-03-31",{"name":101,"class":102},"Zydus Therapeutics Inc.","INDUSTRY",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":49},"100579535","phase-1-evaluate-pk--safety-of-saroglitazar-in-subjects-with-moderate-hepatic-impairment-due-to-cholestatic-liver-disease-100579535","NCT06825559","Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease","A Phase 1, Open-label, Single Arm Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Saroglitazar Magnesium Dosed on Alternate Days in Subjects Having Moderate Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease","Inclusion Criteria:\n\n1. Male and\u002For female aged 18 to 80 years (both inclusive) at the time of signing the ICF.\n2. Body mass index within the range 18.0 to 48.0 kg\u002Fm2 (inclusive) at screening.\n3. Ability to swallow and retain oral medication.\n4. Subjects having documented history of hepatic impairment with cirrhosis due to cholestatic liver disease having Child-Pugh Turcotte score 7 to 9. If the hepatic impairment classification for the subject is not the same at screening and Day -1, enrolment of the subject into a hepatic category group will be at the discretion of the investigator.\n5. Laboratory test values must be clinically acceptable to the investigator and meet all the following parameters at screening:\n\n   Alkaline Phosphatase \\> upper limit of normal Alanine aminotransferase\u002FAspartate aminotransferase value ≤ 10 × upper limit of normal Absolute neutrophil count ≥ 750\u002Fmm3 Platelets ≥ 25,000\u002Fmm3 Hemoglobin ≥ 8 g\u002FdL α-fetoprotein \\\u003C50 ng\u002FmL or 50-80 ng\u002FmL with negative imaging study (Ultrasound \\[US\\], computed tomography scan \\[CT\\], Magnetic Resonance Imaging \\[MRI\\]). Imaging study that excluded presence of liver cancer (US in the preceding 6 months and CT or MRI in the preceding 1 year)\n6. Must provide written informed consent and agree to comply with the trial protocol.\n\nExclusion Criteria:\n\n1. Any significant or unstable medical condition or other instability that would prevent the subject from participating in the study as determined by the investigator\n2. History of malignancy of any type in the last 3 years of screening, with the exception of the following: in situ cervical or breast cancer or surgically excised non-melanoma skin cancers (i.e., basal cell or squamous cell carcinoma).\n3. History of stomach or intestinal surgery or resection within 6 months of screening that would potentially alter absorption and\u002For excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed).\n4. The history of any significant drug allergy (such as anaphylaxis) deemed clinically relevant by the investigator.\n5. Any major surgery within 3 months of screening.\n6. Donation of blood or blood products within 3 months of screening.\n7. Active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment or symptoms of active infectious disease within 2 weeks of screening.\n8. Receiving or has received any investigational drug within 30 days or 5 half-lives (whichever is longer), before receiving Saroglitazar Magnesium.\n9. Estimated glomerular filtration rate (\\\u003C45 mL\u002Fmin\u002F1.73 m2 by CKD-EPI 2021 formula at screening.\n10. Any individual with poor peripheral venous access.\n11. Receipt of blood products within 1 month of check in.\n12. Human immunodeficiency virus type 1 antibody positive at screening.\n13. Other known causes of liver disease, such as non-alcoholic steatohepatitis , alcoholic steatohepatitis, autoimmune hepatitis, or acute or chronic viral hepatitis (including Hepatitis B and C) as determined by the investigator and subject's medical records.\n14. Subjects who have had a change in hepatic disease status within 30 days of screening, as documented by the subject's medical history and deemed clinically significant by the investigator.\n15. Subjects having - History of gastrointestinal bleeding within 1 month of screening. Current functioning organ transplant. Evidence of severe ascites requiring frequent paracentesis in the opinion of the investigator.\n16. Pregnancy-related exclusions, including:\n\nPregnant\u002Flactating female (including positive pregnancy test at screening) Pregnancy should be avoided by male and female subjects either by true abstinence or the use of an acceptable effective contraceptive measures for the duration of the study and for at least 1 month after the end of the study treatment.",{"count":5,"type":21},[86],"Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease",[27],[92,115,116,117],"Primary Biliary Cholangitis","PBC","Pharmacokinetics","2025-10-22",{"date":120,"type":41},"2025-10-24",{"date":122,"type":41},"2025-08-05",{"date":124,"type":21},"2025-12-31",{"name":101,"class":102},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100576126","genotype-phenotype-relationship-between-cryptogenic-cholestasis-and-familial-intrahepatic-cholestasis-100576126","NCT06781242","Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis","Genotype-phenotype Relationship Between Adult Cryptogenic Cholestasis and Mutations in Genes Responsible for Progressive Familial Intrahepatic Cholestasis","Inclusion Criteria:\n\n* age ≥ 18 years\n* diagnosis of PFIC\u002FCCLDs\u002FHBCs\n* obtaining informed consent\n\nExclusion Criteria:\n\n* Another documented cause of chronic liver disease capable of justifying the clinical phenotype",{"count":134,"type":21},300,"OBSERVATIONAL","Genotype-phenotype relationship between adult cryptogenic cholestasis and mutations in genes responsible for progressive familial intrahepatic cholestasis",[27,138,65,139],"Intrahepatic Cholestasis","Hepatobiliary Cancer","2025-01-13",{"date":142,"type":41},"2025-01-17",{"date":144,"type":41},"2024-01-16",{"date":146,"type":21},"2025-09",{"name":148,"class":48},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",2,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":156,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},"100575871","familial-intrahepatic-cholestasis-related-genes-associated-with-disease-susceptibility-in-hepato-biliary-cancers-100575871","NCT06777914","Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers","Inclusion Criteria:\n\n* Instrumental or histological diagnosis of HBCs, defined as primary liver and\u002For biliary tumors (hepatocellular carcinoma, cholangiocarcinoma, hepatocholangiocarcinoma) occurring in patients without apparent underlying chronic liver disease or in the context of cryptogenic chronic liver disease;\n* Curative treatment through surgical resection of the neoplasm or liver transplantation\n* Diagnosis of CCLDs defined as:\n\n  1. GGT and\u002For alkaline phosphatase \\>1.5 times the normal values in two or more measurements taken at least 6 months apart,\n  2. A history of pruritus combined with \\[BA\\] \\>10 mmol\u002Fl for a period of ≥6 months.\n* Obtaining written informed consent\n\nExclusion Criteria:\n\n* Other documented causes of chronic liver disease that can justify the clinical phenotype include:\n\nPrimary biliary cholangitis Primary sclerosing cholangitis IgG4-related cholangiopathy Obstructive jaundice excluded by the demonstration of normal bile duct anatomy Negative virological tests for HBV, HCV, HEV Alcohol abuse Hemochromatosis Wilson's disease Alpha-1 antitrypsin deficiency","12 Months",{"count":158,"type":21},600,"This is a cross-sectional, multicenter tissue study with an exploratory aim to estimate the prevalence of genetic mutations that predispose individuals to diseases in the context of cholestatic disorders and hepatobiliary neoplasms. It is intended as a hypothesis-generating study for future empirical investigations.",[161,162,27],"Hepatobiliary Cancers","Progressive Familial Intrahepatic Cholestasis (PFIC)","2025-01-10",{"date":165,"type":41},"2025-01-16",{"date":167,"type":41},"2024-10-22",{"date":169,"type":21},"2027-10",{"name":148,"class":48},5]